publication date: Dec. 6, 2019
Issue 45 - Dec. 6, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • LOWY: Paylines are dropping because NCI is drawing more applicants who would’ve previously gone elsewhere

    After an examination of the causes of an avalanche of grant applications directed at NCI, institute officials found that new applications largely come from principal investigators  who are switching their research focus to cancer. No other  NIH institute or center faces such pressure.

  • NCI Director’s Report

    Sharpless reflects on his time at FDA: “The engine producing new cancer therapies and diagnostics is doing very well”

    The progress in cancer exceeds that of any other therapeutic area right now—at least as far as FDA is concerned, NCI Director Ned Sharpless said at a Dec. 3 joint meeting of the Board of Scientific Advisors and the National Cancer Advisory Board.

  • Senate committee votes 18-5 in support of Hahn, but questions his commitment to aggressive e-cigarette policy

    A Senate committee Dec. 3 cleared the path for Stephen M. Hahn to become the next FDA commissioner, though some Democratic and Republican senators voiced concerns that he wouldn’t take aggressive action to ban flavored e-cigarettes in this role.

  • AACR, Research!America urge Congress to pass spending bill with funding boost for health agencies

    The American Association for Cancer Research and Research!America are urging Congress to pass the FY20 appropriations bill by Dec. 20.

  • In Brief

    • Williams, Ingram, Mitchell to join President’s Cancer Panel
    • Belani named IASLC chief science officer
    • ACCC project focuses on multidisciplinary cutaneous squamous cell carcinoma care
    • Nimer receives Oscar de la Renta Endowed Chair in Cancer Research
    • Barker named chief strategy officer at USC Lawrence J. Ellison Institute for Transformative Medicine
    • Car named Agios chief scientific officer
    • Peterson receives $1.4M grant for innovative approach to attacking metastatic TNBC
    • Mt. Sinai receives $1M grant for prostate cancer research
  • Funding Opportunities

    ACS and Flatiron Health launch real-world data impact award

    The American Cancer Society and Flatiron Health launched a joint grant-making program that supports both organizations’ goals of accelerating cancer research and improving treatment and care options for patients.

  • TCCL Logo

  • Clinical Roundup

    • Study finds wide county-level variation in rates of surgery for early-stage lung cancer
    • Tecentriq + Avastin combination demonstrates improvement in OS, PFS in HCC
    • Alunbrig demonstrates reduced risk of death, disease progression in ALK+ NSCLC
    • Experimental targeted therapy may be better for repeat kidney cancer patients than FDA-approved counterpart, study finds
    • Duke researchers develop technique to visually depict how cancer cells grow and spread in colon tissue
  • Drugs & Targets

    • FDA approves Tecentriq + chemo as initial treatment metastatic non-squamous NSCLC indication
    • FDA approves FoundationOne CDx as a Companion Diagnostic for Piqray in new indication
    • FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication
    • FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements
    • China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication
    • Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication
  • NCI Trials

    NCI Trials for December 2019

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Copyright (c) 2020 The Cancer Letter Inc.